A single-arm, multicenter, Phase 2 trial to evaluate efficacy and safety of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease

Sponsor
Eisai

Protocol Number
Eisai E7080-M001-221

To Learn More Call
201-510-0910